Chlamydia Infections - Pipeline Review, H2 2016

Date: September 21, 2016
Pages: 76
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: C81818E4A42EN
Leaflet:

Download PDF Leaflet

Chlamydia Infections - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Chlamydia Infections - Pipeline Review, H2 2016’, provides an overview of the Chlamydia Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chlamydia Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chlamydia Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape of Chlamydia Infections
  • The report reviews pipeline therapeutics for Chlamydia Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Chlamydia Infections therapeutics and enlists all their major and minor projects
  • The report assesses Chlamydia Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Chlamydia Infections
Reasons to buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Chlamydia Infections
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Chlamydia Infections pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope:
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Chlamydia Infections Overview
Therapeutics Development
Pipeline Products for Chlamydia Infections - Overview
Pipeline Products for Chlamydia Infections - Comparative Analysis
Chlamydia Infections - Therapeutics under Development by Companies
Chlamydia Infections - Therapeutics under Investigation by Universities/Institutes
Chlamydia Infections - Pipeline Products Glance
Late Stage Products
Early Stage Products
Chlamydia Infections - Products under Development by Companies
Chlamydia Infections - Products under Investigation by Universities/Institutes
Chlamydia Infections - Companies Involved in Therapeutics Development
Abera Bioscience AB
Genocea Biosciences, Inc.
Lead Discovery Center GmbH
Merck & Co., Inc.
NanoBio Corporation
Prokarium Limited
QureTech Bio AB
SATT IDF Innov SAS
Selecta Biosciences, Inc.
SIGA Technologies, Inc.
Statens Serum Institut
Vault Pharma Inc.
Chlamydia Infections - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Ab-03 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
acALY-18 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Chlamydia trachomatis vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Chlamydia trachomatis vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Chlamydia vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
chlamydia vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Chlamydia vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Chlamydia vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Chlamydia vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Chlamydia vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GEN-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptides to Inhibit CPAF for Chlamydia Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Chlamydia Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Chlamydophila Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Block Virulence for Chlamydia Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
solithromycin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ST-669 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VPI-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Chlamydia Infections - Dormant Projects
Chlamydia Infections - Product Development Milestones
Featured News & Press Releases
Dec 02, 2015: NanoBio's Chlamydia Vaccine Improves Clearance of Bacteria and Prevents Pelvic Inflammatory Disease in Mice
Aug 03, 2015: New Vaccine For Chlamydia to Use Synthetic Biology
Aug 03, 2015: SynbiCITE funds new vaccine for Chlamydia
Aug 12, 2014: Cempra Initiates Phase 3 Clinical Trial in Patients With Uncomplicated Gonorrhea Infection
Jul 20, 2011: Newly Designed Molecule Blocks Chlamydia Bacteria
Dec 15, 2009: Genocea Biosciences Awarded Grant For The Development Of Chlamydia Vaccines From The University Of Pittsburgh Medical Center’s Sexually Transmitted Infections Cooperative Research Center
Sep 13, 2007: Possible Vaccine Target For Chlamydia Identified
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 76

LIST OF TABLES

Number of Products under Development for Chlamydia Infections, H2 2016
Number of Products under Development for Chlamydia Infections - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Chlamydia Infections - Pipeline by Abera Bioscience AB, H2 2016
Chlamydia Infections - Pipeline by Genocea Biosciences, Inc., H2 2016
Chlamydia Infections - Pipeline by Lead Discovery Center GmbH, H2 2016
Chlamydia Infections - Pipeline by Merck & Co., Inc., H2 2016
Chlamydia Infections - Pipeline by NanoBio Corporation, H2 2016
Chlamydia Infections - Pipeline by Prokarium Limited, H2 2016
Chlamydia Infections - Pipeline by QureTech Bio AB, H2 2016
Chlamydia Infections - Pipeline by SATT IDF Innov SAS, H2 2016
Chlamydia Infections - Pipeline by Selecta Biosciences, Inc., H2 2016
Chlamydia Infections - Pipeline by SIGA Technologies, Inc., H2 2016
Chlamydia Infections - Pipeline by Statens Serum Institut, H2 2016
Chlamydia Infections - Pipeline by Vault Pharma Inc., H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Chlamydia Infections - Dormant Projects, H2 2016
Chlamydia Infections - Dormant Projects (Contd..1), H2 2016 69

LIST OF FIGURES

Number of Products under Development for Chlamydia Infections, H2 2016
Number of Products under Development for Chlamydia Infections - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Targets, H2 2016
Number of Products by Stage and Targets, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Herpes Simplex Infections - Pipeline Review, H2 2015 US$ 1,600.00 Sep, 2015 · 185 pages
HIV-1 Infection - Pipeline Review, H2 2015 US$ 1,700.00 Dec, 2015 · 406 pages

Ask Your Question

Chlamydia Infections - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: